Related references
Note: Only part of the references are listed.The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment
Johanna M. Gostner et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Differences in pteridine urinary levels in patients with malignant and benign ovarian tumors in comparison with healthy individuals
M. Zvarik et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2015)
A Prospective Study of the Immune System Activation Biomarker Neopterin and Colorectal Cancer Risk
Krasimira Aleksandrova et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
A Prospective Study of the Immune System Activation Biomarker Neopterin and Colorectal Cancer Risk
Krasimira Aleksandrova et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Fluorescence analysis of urine and its potential for ovarian cancer screening
D. Martinicky et al.
NEOPLASMA (2015)
Genentech dives deeper into the next wave of cancer immunotherapies
Sarah Crunkhorn
NATURE REVIEWS DRUG DISCOVERY (2014)
Urinary Neopterin, Serum Retinol, α-tocopherol and Homocysteine in Breast Cancer Patients During Treatment with Bevacizumab and Chemotherapy
Bohuslav Melichar et al.
PTERIDINES (2013)
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm
Robert J. Kurman et al.
HUMAN PATHOLOGY (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer
Alain G. Zeimet et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Neopterin, a prognostic marker in human malignancies
Robert Sucher et al.
CANCER LETTERS (2010)
Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix
Birgit Volgger et al.
CANCER LETTERS (2008)
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
David S. Alberts et al.
GYNECOLOGIC ONCOLOGY (2008)
Monitoring tryptophan metabolism in chronic immune activation
K Schröcksnadel et al.
CLINICA CHIMICA ACTA (2006)
Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies
B Melichar et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Tryptophan degradation in patients with gynecological cancer correlates with immune activation
K Schroecksnadel et al.
CANCER LETTERS (2005)
Interferon-γ expression is an independent prognostic factor in ovarian cancer
C Marth et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Share Paper
